<DOC>
	<DOCNO>NCT01998672</DOCNO>
	<brief_summary>The purpose study assess safety tolerability FXR agonist Px-102 healthy subject 7 day multiple oral dosing .</brief_summary>
	<brief_title>Multiple Ascending Oral Dose Phase I Study With Px-102</brief_title>
	<detailed_description>The study single-centre , double-blind , randomize , placebo-controlled , parallel group phase I study healthy male subject receive ascend multiple oral oral dos Px-102 ass safety tolerability , pharmacokinetics pharmacodynamics .</detailed_description>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Healthy male subject Caucasian origin 18 45 year age ( inclusive ) . Good state health ( mentally physically ) determine medical history , physical examination , vital sign , ECG record clinical lab result . BMI 2029 kg/m² ( inclusive ) ; absolute weight 70 120 kg . Total cholesterol liver enzyme level [ alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , gammaglutamyltransferase ( GGT ) , alkaline phosphatase ( AP ) ] strictly within normal range screen Day 1 . Serum triglyceride exceed upper limit normal range . HbA1c ≤ 6.5 % Subject inform verbally write give write consent participation study prior start studyrelated procedure . Negative result HIV HepatitisB C serology screen . Subject ( include female partner childbearing potential ) use highly effective method birth control ( failure rate le 1 % per year use consistently correctly ) , e.g . implant , injectables , combine oral contraceptive combination barrier method , intrauterine contraceptive device sexual abstinence . Female gender Use prescription nonprescription drug within 7 day ( 30 drug possible enzyme inducer ) prior administration study medication . Use drug know induce steatosis ( e.g . valproate , amiodarone prednisone ) affect body weight carbohydrate metabolism Any acute chronic illness clinically relevant find screen baseline examination may jeopardize subject 's participation study History presence biliary obstruction biliary disease , hepatic encephalopathy , advanced ascites , portal hypertension , esophageal/gastric variceal bleeding , hepatocellular carcinoma , previous liver transplantation chronic liver disease Renal dysfunction , e.g . glomerular filtration rate ≤ 80 ml/min/1.73 m2 ( determined formula CockroftGault ) Type I II Diabetes Any clinically relevant abnormality screen medical assessment , laboratory examination , 12lead ECG Any clinically relevant find baseline telemetry within predose evaluated observation period least 20 hour Marked baseline prolongation QT/QTc interval ( QTc interval &gt; 440 m ) 12lead ECG use Fridericia method QTc analysis Heart rate &lt; 50 bpm . History pathological cardiovascular symptom severe cardiovascular event History severe chronic autoimmune disease severe allergy , atopic eczema , chronic dermatitis , severe psoriasis , multiple sclerosis , severe asthma , lupus related disorder Allergies ( except mild form hay fever ) history hypersensitivity reaction Smoking ( regular irregular ) &gt; 5 cigarette ( equivalent ) per day Excessive alcohol drinking ( approximately 20 g alcohol per day ) , unable refrain alcohol drink 48 hour prior dose last pharmacokinetic blood sample withdrawn Positive test drug alcohol screen prior dose session History alcoholism drug/chemical/substance abuse within past 2 year Investigator deem subject unable unwilling comply fully study protocol Has receive clinical study medication within last 30 day prior study Donation loss 400 ml blood within eight ( 8 ) week prior dose Allergic active inactive ingredient study medication Any reason Investigator consider unsuitable subject participate Any condition previous disease lead pruritus itch skin .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>